End Of Exanta: AstraZeneca Drops Drug After New Report Of Liver Injury
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm is pulling its U.S. application for the anticoagulant and will remove the drug from European markets following a report of serious liver injury.
You may also be interested in...
AstraZeneca Executive VP, Discovery Research, Jan Lundberg: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
AstraZeneca's chief of discovery research discusses his company's pipeline, its plans related to the acquisitions of MedImmune and CAT, and whether the Exanta compound has any developmental future with "The Pink Sheet" DAILY.
AstraZeneca Executive VP, Discovery Research, Jan Lundberg: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
AstraZeneca's chief of discovery research discusses his company's pipeline, its plans related to the acquisitions of MedImmune and CAT, and whether the Exanta compound has any developmental future with "The Pink Sheet" DAILY.
Boehringer Ingelheim’s Dabigatran Demonstrates Non-Inferiority To Lovenox
The drug maker is in discussions with U.S. regulators regarding submission for venous thromboembolism, but has not released a filing timeline.